Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis-Reference-Cited by-同舟云学术

Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis

Published:2020-06-14 Issue:2 Volume:35 Page:468-475
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Barosi Giovanni^ORCID,Rosti Vittorio,Catarsi Paolo^ORCID,Villani Laura,Abbà Carlotta,Carolei Adriana,Magrini Umberto,Gale Robert Peter,Massa Margherita,Campanelli Rita

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0926-6.pdf

Reference27 articles.

1. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel J-P, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123–e133.

2. Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N. Engl J Med. 2018;379:1416–30.

3. Rao TN, Hansen N, Hilfiker J, Rai S, Majewska J-M, Lekovic D, et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019;134:1832–46.

4. Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, et al. Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells. Cancer Res. 2019;79:1938–51.

5. Rosti V, Campanelli R, Massa M, Viarengo G, Villani L, Poletto V, et al. Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis. Am J Hematol. 2016;91:709–13.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis;Cancers;2024-07-16

2. Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis;Clinical and Experimental Medicine;2024-07-08

3. Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?;Blood Cancer Journal;2024-01-23

4. Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms;American Journal of Hematology;2023-03-09

5. Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype;Acta Haematologica;2022-11-07